Monopar Therapeutics Inc. (MNPR) Financial Statements
Free cash flow over the same period: -$12.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MNPRMonopar Therapeutics Inc.Follow MNPR — free
—
Price chart with a free account
- Market cap
- 474.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | 0.9 | 1.8 | 2.0 | 4.1 | 6.5 | 7.6 | 5.6 | 13.0 | 9.9 | 14.8 | |
| Operating income | -16.6 | -3.3 | -4.3 | -6.5 | -9.1 | -10.5 | -8.8 | -16.2 | -16.7 | -22.1 | |
| Pre-tax income | -16.6 | -3.3 | -4.2 | -6.3 | -9.1 | -10.5 | -8.4 | -15.6 | -13.7 | -17.8 | |
| Income tax | -0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -16.6 | -3.2 | -4.2 | -6.3 | -9.1 | -10.5 | -8.4 | -15.6 | -13.7 | -17.8 | |
| Diluted EPS ($) | -1.89 | -0.35 | -0.45 | -0.58 | -0.73 | — | — | — | — | — |
USD millions · SEC XBRL
Monopar Therapeutics Inc. — questions
- What is Monopar Therapeutics Inc.'s net income?
- -$17.8M over the twelve months to 2026-06-30.
- What is Monopar Therapeutics Inc.'s free cash flow?
- -$12.2M over the twelve months to 2026-06-30.
Every figure on this page comes from Monopar Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.